Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...
Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...
Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...
As the festive season approaches, experts have a warning for those taking prescription GLP-1 receptor agonist drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback